ENTITY META 10-19

META 10-19

PulseAugur coverage of META 10-19 — every cluster mentioning META 10-19 across labs, papers, and developer communities, ranked by signal.

Total · 30d

1

1 over 90d

Releases · 30d

0

0 over 90d

Papers · 30d

0

0 over 90d

TIER MIX · 90D

TOPICS

TIMELINE

2026-11-02 product_launch Leman Biotech's META 10-19, a metabolically enhanced CAR-T therapy, has shown promising results in early clinical trials, achieving a 100% complete remission rate with significantly reduced dosage. source

SENTIMENT · 30D

1 day(s) with sentiment data

RECENT · PAGE 1/1 · 1 TOTAL

SIGNIFICANT · CL_336677 · Nov 2 · 06:15

Leman Biotech's low-dose CAR-T therapy shows 100% remission rate

Leman Biotech has developed a novel CAR-T cell therapy that utilizes a significantly lower dosage, just 1‰ of the conventional amount, while achieving remarkable efficacy. This approach, which involves metabolically enh…